The combination of IFNα (IFNα2b) and IF Nβ1b with other antiviral agents (lopinavir/ritonavir, ribavirin and/or remdesivir), as has been reported for the treatment of COVID-19 (1) and in clinical trials (Open-label Randomized Controlled Trial: NCT04276688), with the aim of increasing the efficacy of the antiviral drugs remains to be further investigated. The gene discussed is IFNA2; the disease is COVID-19.